CT103A

DB18180InvestigationalCell transplant therapies

CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 17
Curator reviewed
Code names: CT-103A

Resolves to

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with CT103A, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.